General Anxiety
Conditions
Interventions
Buspirone Group: formed by 7 women who will use the medication buspirone hydrochloride every 8 hours, for 90 days
Placebo Group: formed by 7 women who will use placebo medication every 8 hours, for 90 days
Non-pharmacological group: formed by 7 women who will receive Google Forms links via Whatsapp, for 90 days.
The minimum daily dose of the buspirone hydrochloride is 5mg every 8 ours and the optimal th
Sponsors
Universidade Federal do Paraná
Universidade Federal do Paraná
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: female volunteers, over 18 years old, diagnosed with definitive awake bruxism
Exclusion criteria
Exclusion criteria: participants who do not agree to participate in this study or who have some cognitive difficulty that prevents them from answering the questionnaires; under 18 years old; individuals with epilepsy; with acute intoxication and/or chronic use of alcohol, hypnotics, analgesics, or antipsychotic drugs; with severe kidney and liver failure; history of seizure; current illness or history of serious neurological or psychiatric disorders; history of chronic musculoskeletal pain; previous diagnosis or signs and symptoms of other chronic temporomandibular disorders; use of prescription drugs or drugs with possible effects on sleep or changes in motor behavior or drug interactions with buspirone hydrochloride; smoking; currently undergoing medical or dental treatment; with some dental characteristics, such as loss of more than two posterior teeth, except third molars and users of complete dentures, removable partial dentures and orthodontic appliances.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| o evaluate the effect of buspirone hydrochloride on the frequency of awake bruxism as a somatic manifestation of anxiety , through a symptom questionnaire and through the Diagnostic Criteria for Temporomandibular Disorders (CD) /TMD), Generalized Anxiety Disorders Questionnaire (GAD-7), Depression Symptom Severity Questionnaire (PHQ-9), and Oral Behavior Verification Questionnaire (OBC), clinical assessment when the presence of signs of brain activity bruxism, electromyography exam (EMG - NeuroUp) and ecological assessment method (EMA) through apps. The frequency of bruxism as a somatic manifestation of anxiety is expected to decrease with the use of buspirone hydrochloride. | — |
Secondary
| Measure | Time frame |
|---|---|
| to evaluate the association between wakefulness bruxism Anxiety, verified by the GAD-7 entity. We will see if there is an association between wakefulness bruxism and anxiety.;To evaluate the association between wakefulness bruxism and Anxiety and Depression, verified by the PHQ-9 questionnaires. We will observe if there is an association between wakefulness bruxism and depression.;To evaluate the alteration pattern caused by buspirone hydrochloride in the electromyography exam, verified by the electromyography exam itself. We will observe if there is any kind of change in the electromyography exam with the use of medication. | — |
Countries
Brazil
Contacts
Public ContactJordana Senff
Universidade Federal do Paraná
Outcome results
None listed